Holen Sie sich die Stockscreener-App
1.33
0.76%
0.01
Handel nachbörslich:
1.33
Schlusskurs vom Vortag:
$1.32
Offen:
$1.31
24-Stunden-Volumen:
3.30M
Relative Volume:
0.65
Marktkapitalisierung:
$249.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-1.243
EPS:
-1.07
Netto-Cashflow:
$-75.59M
1W Leistung:
+13.68%
1M Leistung:
-22.22%
6M Leistung:
-47.43%
1J Leistung:
-69.98%
1-Tages-Spanne:
$1.30
$1.35
1-Wochen-Bereich:
$1.09
$1.35
52-Wochen-Spanne:
$1.09
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.33 | 247.20M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-27 | Eingeleitet | Barclays | Overweight |
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
HumacyteOn Nov 21, co delivered notice to Jefferies terminating open market sale agreement entered on Sept 1, 2022 - MarketScreener
Humacyte Ends Sale Agreement with Jefferies LLC - TipRanks
What catalysts could drive Humacyte Inc. stock higherJuly 2025 Analyst Calls & Consistent Profit Alerts - BỘ NỘI VỤ
Humacyte’s Major Breakthroughs Impress Investors: Market Reactions - StocksToTrade
Humacyte Inc. (HUMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
D. Boral Capital Maintains Humacyte (HUMA) Buy Recommendation - MSN
Humacyte (HUMAW) Stock Price, News & Analysis - MarketBeat
Humacyte, Inc. (HUMA) stock price, news, quote and history - Yahoo Finance UK
Quantitative breakdown of Humacyte Inc. recent moveMarket Movers & Long-Term Growth Plans - newser.com
Humacyte releases press info on VEITH symposium presentation - Traders Union
D. Boral Capital Reiterates "Buy" Rating for Humacyte (HUMA) | H - GuruFocus
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results - The Manila Times
Humacyte (Nasdaq: HUMA) Details ATEV Recellularization and 2-Year Trauma Data - Stock Titan
What recovery options are there for Humacyte Inc. Equity WarrantWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
Real time pattern detection on Humacyte Inc. stockPortfolio Gains Report & Step-by-Step Trade Execution Guides - newser.com
Will Humacyte Inc. Equity Warrant stock see insider buyingDividend Hike & Real-Time Stock Movement Alerts - newser.com
Will Humacyte Inc. see short term momentumJuly 2025 Sector Moves & Stepwise Trade Execution Plans - newser.com
Will Humacyte Inc. stock deliver shareholder valueJuly 2025 Summary & Risk Controlled Daily Plans - newser.com
Is Humacyte Inc. stock supported by strong cash flows2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
How to interpret RSI for Humacyte Inc. stock2025 Valuation Update & Precise Buy Zone Identification - newser.com
Multi asset correlation models including Humacyte Inc. Equity WarrantWeekly Trade Review & Verified Short-Term Plans - newser.com
Is Humacyte Inc. Equity Warrant stock ready for a breakoutInsider Selling & Real-Time Price Movement Reports - newser.com
Is Humacyte Inc. Equity Warrant stock attractive for retirement portfolios - newser.com
Is Humacyte Inc. Equity Warrant stock attractive for growth ETFsQuarterly Trade Review & Daily Risk Controlled Trade Plans - newser.com
Will Humacyte Inc. stock benefit from infrastructure spendingEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Using RSI to spot recovery in Humacyte Inc. Equity Warrant2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Humacyte Inc: Is It a Time of Strategic Shift? - StocksToTrade
[Form 4] Humacyte, Inc. Insider Trading Activity - Stock Titan
Humacyte introduces Symvess at Veith Symposium - Traders Union
Technical analysis overview for Humacyte Inc. Equity Warrant stockJuly 2025 Opening Moves & Detailed Earnings Play Strategies - newser.com
Earnings visualization tools for Humacyte Inc.Market Rally & Weekly Stock Performance Updates - newser.com
Chart overlay techniques for tracking Humacyte Inc.2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
Can Humacyte Inc. stock reach $100 price targetJuly 2025 PostEarnings & AI Based Buy/Sell Signal Reports - newser.com
Key metrics from Humacyte Inc.’s quarterly dataQuarterly Portfolio Summary & AI Powered Market Entry Ideas - newser.com
Should I hold or sell Humacyte Inc. Equity Warrant stock in 2025Chart Signals & Verified Short-Term Plans - newser.com
Will Humacyte Inc. stock attract more institutional investorsLong Setup & Weekly Return Optimization Plans - newser.com
Is Humacyte Inc. stock trading near support levels2025 Price Targets & Reliable Breakout Stock Forecasts - newser.com
What analysts say about Humacyte Inc Equity Warrant stockMarket Breadth Indicators & Outstanding Capital Returns - earlytimes.in
Is Humacyte Inc. stock cheap compared to fundamentalsJuly 2025 Pullbacks & Expert Verified Movement Alerts - newser.com
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):